Free Trial

PMV Pharmaceuticals Q1 2023 Earnings Report

PMV Pharmaceuticals logo
$1.50 0.00 (0.00%)
(As of 12/20/2024 05:30 PM ET)

PMV Pharmaceuticals EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

PMV Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PMV Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

PMV Pharmaceuticals Earnings Headlines

PMV Pharmaceuticals files $200M mixed securities shelf
PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
Oppenheimer Sticks to Its Hold Rating for PMV Pharmaceuticals (PMVP)
PMV Pharmaceuticals (PMVP) Gets a Buy from Craig-Hallum
See More PMV Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email.

About PMV Pharmaceuticals

PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

View PMV Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings